Studio CAPIRE

Coronary Atherosclerosis in outlier subjects:
Protective and Individual Risk factor Evaluation

Ultimo aggiornamento 7 maggio 2018

Appendix

Steering Committee

A. Maseri (Chairman; Firenze), D. Andreini (Milano), S. Berti (Massa), M. Canestrari (Fano), G. Casolo (Lido di Camaiore), D. Gabrielli (Fermo), R. Latini (Milano), M. Magnoni (Milano), P. Marraccini (Pisa), S. Masson (Milano), T. Moccetti (Lugano), M.G. Modena (Modena)

Imaging Core Laboratory: D. Andreini, G. Pontone (Centro Cardiologico Monzino Milano)

Centralized biobank and biomarker core laboratory: S. Masson, F. Gaspari, S. Ferrari, A. Cannata, N. Stucchi, M. Fois, R. Bernasconi, G. Balconi (Istituto Mario Negri, Milano and Bergamo), T. Vago, T. Letizia (Ospedale Luigi Sacco, Milano), B. Bottazzi, R. Leone (Istituto Clinico Humanitas, Rozzano).

Central ECG Reading: I. Suliman (Centro Studi ANMCO, Firenze)

Psychologists CRF Group: M. Sommaruga (IRCCS Salvatore Maugeri Unità di Psicologia, Milano), P. Gremigni (Dipartimento di Psicologia Università di Bologna)

Participating Centers and Investigators

Fano, Ospedale S Croce (R. Olivieri); Fermo, Ospedale Civile A. Murri (L. Pennacchietti); Lido di Camaiore, Nuovo Ospedale Versilia (M. Magnacca); Lugano, Cardiocentro Ticino (M.G. Rossi, E. Pasotti, T. Moccetti); Massa, FTGM - Stabilimento di Massa (A. Clemente); Milano, Centro Cardiologico Monzino (D. Andreini, G. Pontone, S. Mushtaq); Modena, Ospedale Policlinico (E. Mauro, R. Rossi); Parma, AOU. di Parma (F. Pigazzani); Pisa, AOU Pisana (L. Faggioni); Pisa, FTGM - Stabilimento di Pisa (M. Ciardetti); Udine, AOU SM della Misericordia (M. Puppato)

Centro di Coordinamento
Centro Studi ANMCO

Via La Marmora, 34
50121 Firenze - Italia

Tel. +39 055 5101354

Fax +39 055 5101310

SUPPLEMENTARY DATA

Supplementary Table 1
Multiple regression of plasma renin levels.*

	Estimate	**SE**	***t* Ratio**	***p***
Intercept	9.656	0.194	49.90	1e-197
Sex (F)	-0.09	0.026	-3.40	7.2e-4
Age (years)	0.005	0.003	1.51	1.3e-1
ACEi (none)	-0.07	0.033	-1.97	4.9e-2
ARBs (none)	-0.07	0.036	-1.80	7.3e-2
Diuretics (none)	-0.07	0.044	-1.65	1e-1
Statins (none)	-0.08	0.028	-2.68	7.6e-3
ß-blockers (none)	-0.05	0.029	-1.70	9e-2
CAD (presence)	0.083	0.029	2.88	4.1e-3
T2D (absence)	-0.09	0.039	2.23	2.7e-2

*log-transformed; adjusted r^2 = 0.16, p=6.4e-17.

Multiple regression of plasma adiponectin levels.*

	Estimate	**SE**	***t* Ratio**	***p***
Intercept	7.23	0.129	56.08	3e-219
Sex (F)	0.128	0.017	7.33	9e-13
Age (years)	0.01	0.002	5.08	5.3e-7
ACEi (none)	-0	0.022	-0.12	9e-1
ARBs (none)	0.044	0.024	1.81	7e-2
Diuretics (none)	-0.03	0.029	-1.15	2.5e-1
Statins (none)	0.001	0.019	0.05	9.6e-1
ß-blockers (none)	0.047	0.019	2.47	1.4e-2
CAD (presence)	-0.08	0.019	-4.26	2.5e-5
T2D (absence)	0.116	0.026	4.49	8.9e-6

*log-transformed; adjusted r^2 = 0.26, p=1.5e-29.

©2020 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc19-1902/-/DC1

SUPPLEMENTARY DATA

Supplementary Table 2 – CCTA parameters.

	NGT	T2D	*p*
Myocardial mass (g/m^2)	119 ± 27	117 ± 22	0.76
Lumen stenosis >70%, n (%)	64 (44)	17 (47)	0.09
>2 stenoses >70%, n (%)	20 (14)	8 (22)	0.21
Segment Stenosis Score (units)	11.4 ± 5.4	12.3 ± 7.3	0.43
Segment Involvement Score (units)	7.6 ± 1.9	7.6 ± 2.3	0.97
Plaque total volume (mm^3)	227 ± 164	222 ± 230	0.88
Plaque length (mm)	46.8 ± 24.6	40.9 ± 33.8	0.23
Remodelling Index, n (%)	87 (60)	19 (53)	0.40
Low Attenuation Plaque (mm^3)	8.6 ± 16.6	9.4 ± 17.2	0.8
Spotty Calcifications, n (%)	58 (40)	11 (31)	0.28
Non-calcified fibro-fatty plaque (mm^3)	49.0 ± 58.6	55.6 ± 76.2	0.57

©2020 American Diabetes Association. Published online at http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc19-1902/-/DC1